FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 809 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... May 8, 2023 Pride 2023: Taking on the inequalities in LGBTQ+ cancer care June 23, 2023 How Anxiety Impacts People With Cancer and How to Cope February 10, 2022 Cancer in My Community: Advancements in Cancer Care in Singapore December 2, 2021 Load more HOT NEWS Pediatricians’ Offices Can Help Parents Quit Smoking, Study Shows Jonas Brothers Visit Fan In Hospital Who Missed Their Concert Due... How and When to Wash Your Reusable Cloth Mask and When... Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback
